| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Multiple targets including antioxidant enzymes, estrogen receptors, and inflammatory mediators. 7,2′-Dihydroxy-3′,4′-dimethoxyisoflavan 7-O-β-D-glucoside, as an isoflavan glycoside, may exhibit antioxidant activity by scavenging free radicals. It may interact with estrogen receptors (ERα and ERβ) due to its structural similarity to other isoflavonoids. The compound may have anti-inflammatory effects by inhibiting the production of pro-inflammatory mediators. Its anticancer activity may involve inhibition of cell proliferation and induction of apoptosis.
|
|---|---|
| ln Vitro |
The compound exhibits biological activities typical of isoflavan glycosides, including antioxidant and potential estrogenic effects. It may scavenge free radicals and reduce oxidative stress in various in vitro systems. Its estrogenic activity may be assessed using cell-based reporter assays. The compound may also show anti-inflammatory effects by inhibiting the production of inflammatory mediators. Its specific in vitro activities would depend on the concentrations tested and the assay systems used. Further studies are needed to fully characterize its activity profile.
|
| ln Vivo |
In vivo studies of 7,2′-dihydroxy-3′,4′-dimethoxyisoflavan 7-O-β-D-glucoside are limited. As an isoflavan glycoside, it is expected to be metabolized by intestinal microbiota to release the aglycone, which may be absorbed systemically. Isoflavonoids are known for their estrogenic effects and have been studied for their potential benefits in menopausal symptoms, osteoporosis, and cancer prevention. Further studies are needed to characterize the compound's specific in vivo activities.
|
| Enzyme Assay |
Non-cell-based assays for 7,2′-dihydroxy-3′,4′-dimethoxyisoflavan 7-O-β-D-glucoside include standard antioxidant assays such as DPPH radical scavenging, ABTS radical scavenging, and FRAP assays. Estrogen receptor binding can be assessed using competitive binding assays with radiolabeled estradiol. Anti-inflammatory activity can be assessed by measuring inhibition of COX-2, LOX, or cytokine production in enzyme assays. Standard analytical methods including HPLC, NMR, and mass spectrometry are used for compound characterization.
|
| Cell Assay |
Cell-based assays for the compound use various cell lines to assess its biological activities. Estrogen receptor activity is assessed using MCF-7 breast cancer cells (ER-positive) or reporter gene assays with an estrogen response element (ERE)-luciferase construct. Macrophage cell lines (e.g., RAW 264.7) are stimulated with LPS and treated with the compound, and inflammatory mediators in culture supernatant are measured. For antioxidant studies, cells are exposed to oxidative stress inducers and treated with the compound, and intracellular ROS levels are measured. Anticancer activity is assessed in cancer cell lines.
|
| Animal Protocol |
In vivo studies of 7,2′-dihydroxy-3′,4′-dimethoxyisoflavan 7-O-β-D-glucoside are limited. Based on its biological activities, potential animal models include: ovariectomized rat models for estrogenic effects; and tumor xenograft models for anticancer evaluation. Standard protocols for these models involve administration of the compound followed by measurement of relevant endpoints.
|
| ADME/Pharmacokinetics |
The compound has a molecular formula of C₂₃H₂₈O₁₀ and a molecular weight of approximately 464.46 g/mol. It is an isoflavan glycoside. The compound is soluble in organic solvents such as DMSO and methanol. It should be stored as a powder at -20°C for up to 3 years or in solvent at -80°C for 1 year. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for 7,2′-dihydroxy-3′,4′-dimethoxyisoflavan 7-O-β-D-glucoside are limited. Isoflavonoids are generally considered to have low toxicity. However, comprehensive toxicological studies have not been reported. Standard laboratory safety practices should be followed when handling this compound, including the use of personal protective equipment. It is intended for research use only.
|
| References | |
| Additional Infomation |
Verbenaol 7-O-glucoside is an aldose glycoside and isoflavone compound.
7,2′-Dihydroxy-3′,4′-dimethoxyisoflavan 7-O-β-D-glucoside is a naturally occurring isoflavan glycoside found in various plant species. Isoflavans are a class of flavonoids known for their diverse biological activities, including antioxidant, anti-inflammatory, anticancer, and estrogenic effects. The compound is used as a reference standard for the identification and quantification of isoflavans in plant extracts and for research purposes. Its structural features, including hydroxyl and methoxy groups, contribute to its biological activities. It is for research use only. |
| Molecular Formula |
C23H28O10
|
|---|---|
| Molecular Weight |
464.46
|
| Exact Mass |
464.168
|
| CAS # |
94367-43-8
|
| PubChem CID |
125142
|
| Appearance |
White to off-white solid
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
641.5±55.0 °C at 760 mmHg
|
| Flash Point |
341.8±31.5 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.629
|
| LogP |
0.59
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
33
|
| Complexity |
622
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
OC1C(OC)=C(OC)C=CC=1C1COC2C=C(C=CC=2C1)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
|
| InChi Key |
SXHOGLPTLQBGDO-ZPHFBNLKSA-N
|
| InChi Code |
InChI=1S/C23H28O10/c1-29-15-6-5-14(18(25)22(15)30-2)12-7-11-3-4-13(8-16(11)31-10-12)32-23-21(28)20(27)19(26)17(9-24)33-23/h3-6,8,12,17,19-21,23-28H,7,9-10H2,1-2H3/t12?,17-,19-,20+,21-,23-/m1/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[[3-(2-hydroxy-3,4-dimethoxyphenyl)-3,4-dihydro-2H-chromen-7-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| Synonyms |
7,2′-Dihydroxy-3′,4′-dimethoxyisoflavan 7-O-β-D-glucoside
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (215.30 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1530 mL | 10.7652 mL | 21.5304 mL | |
| 5 mM | 0.4306 mL | 2.1530 mL | 4.3061 mL | |
| 10 mM | 0.2153 mL | 1.0765 mL | 2.1530 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
